Investor Presentaiton
Major R&D Pipeline: Alpha
As of Jul 2022
Daiichi-Sankyo
DS-7300 (JP/US)
B7-H3-directed ADC
ESCC, CRPC, squamous NSCLC, etc.
DS-6000 (US)
CDH6-directed ADC
Renal cell carcinoma, ovarian cancer
DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors
DS-1211 (US)
TNAP inhibitor
Pseudoxanthoma elasticum
DS-6016 (JP)
Anti-ALK2 antibody
FOP
DS-7011 (US)
Anti-TLR7 antibody
Systemic lupus erythematosus
DS-2325 (US)
KLK5 inhibitor
Netherton syndrome
Oncology
Specialty medicine
Vaccine
Phase 1
PLX2853 (US)
BET inhibitor
AML
PLX2853 (US)
BET inhibitor
Solid tumor
Phase 2
Valemetostat (DS-3201) (JP/US/EU/Asia)
EZH1/2 inhibitor
PTCL
DS-1001 (JP)
Phase 3
Filed
Valemetostat (DS-3201) (JP)
EZH1/2 inhibitor
Pexidartinib (JP/Asia)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor
ATL/L
Quizartinib (JP/US/EU/Asia)
PLX2853 (US)
BET inhibitor
Gynecologic neoplasms, ovarian cancer
PLX2853 (US)
Valemetostat (DS-3201) (EU)
EZH1/2 inhibitor
BCL
Mutant IDH1 inhibitor.
Glioma
DS-7300 (JP/US/EU/Asia)
B7-H3-directed ADC
ES-SCLC
DS-5141 (JP)
ENA oligonucleotide
DMD
DS-5670 (JP)
COVID-19 mRNA vaccine
COVID-19 (initial vaccination)
FLT3 inhibitor
AML 1L
Esaxerenone (JP)
MR blocker
Diabetic nephropathy
VN-0102/JVC-001 (JP)
Measles mumps rubella combined vaccine
DS-5670 (JP)
COVID-19 mRNA vaccine
COVID-19 (booster vaccination)
BET inhibitor
Prostate cancer
DS-1594 (US)
Menin-MLL binding inhibitor
AML, ALL
DS-9606 (US/EU)
Target undisclosed ADC
Solid tumors
VN-0200 (JP)
RS virus vaccine
RS virus infection
project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
SAKIGAKE Designation (JP)
Orphan drug designation (JP/US/EU)
VN-0107/MEDI3250 (JP)
Live attenuated influenza vaccine nasal
spray
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal
squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma
42View entire presentation